4//SEC Filing
Sanna Bastiano 4
Accession 0001209191-23-028243
CIK 0000875320other
Filed
May 8, 8:00 PM ET
Accepted
May 9, 4:15 PM ET
Size
6.8 KB
Accession
0001209191-23-028243
Insider Transaction Report
Form 4
Sanna Bastiano
EVP, Cell & Genetic Therapies
Transactions
- Sale
Common Stock
2023-05-05$350.03/sh−422$147,713→ 34,888 total - Sale
Common Stock
2023-05-08$350.00/sh−2,850$997,500→ 32,038 total
Footnotes (3)
- [F1]Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
- [F2]Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $350.03 (range $350.00 to $350.40).
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001829069
Filing Metadata
- Form type
- 4
- Filed
- May 8, 8:00 PM ET
- Accepted
- May 9, 4:15 PM ET
- Size
- 6.8 KB